Technology
Shorts, Cornered
June 3, 2025
While faith in most media outlets is riding an all-time low, one name still carries sunny optimism: The Weather Channel. It’s America’s most trusted source for news, with a 49% net trust score this year. BBC and PBS follow close behind — but one major name plummeted to 26th place. You can guess which one.
Markets shook off early jitters to finish strong on Monday. The S&P 500 climbed 0.4%, the Nasdaq 100 rose 0.7%, and the Russell 2000 edged up 0.2%. Energy led the charge despite OPEC+ pumping more oil, and tech had another solid day.
Even with the federal $7,500 EV tax credit likely off the table when production begins in Indiana next year, Slate Auto’s debut truck — the “Blank Slate” — will still roll in under most used car price tags. Jeff Jablansky, Slate’s PR lead, told Sherwood News that the sticker will stay in the “mid-$20,000s” range.
Here’s the twist: Slate isn’t just eyeing new car buyers. They're gunning for the used market — which moves more than double the volume of new car sales annually in the U.S.
Depending on who you ask, the average used car in America runs between $25,500 (Kelley Blue Book) and $28,000 (CarGurus). So yeah, this truck’s price is no accident. And Jablansky insists it’s not budging.
Customization is another ace up Slate’s sleeve. The truck is modular, which opens the door to personal touches — for a fee, of course. So far, more than 100,000 people have put down refundable reservations. Thanks to Slate’s online builder, nearly 8 million dream trucks have been mocked up. There’s no clear “favorite” build, but Jablansky sees something deeper in all the tinkering: real buyer intent.
Slate’s clever pricing already makes it a standout among new EVs, but aiming at the used market dramatically broadens the field. We’re also intrigued by “Slate University,” the company’s DIY repair initiative — where buyers can learn to fix their own vehicle. Whether that means wrenching our way out of a fender bender is TBD.
Presented by Turn Therapeutics
When faced with a deadly infection boasting a 70% fatality rate and no existing cure, Bradley Burnam did what most wouldn’t dare—he created the solution himself. Enter Hexagen: a groundbreaking formula that Burnam personally shepherded through the FDA clearance process for just $24,000. But he didn’t stop there. Building on this success, Burnam expanded the technology, secured two additional FDA clearances, and founded a company that’s rewriting the rules on self-made medical innovation: Turn Therapeutics.
Hexagen isn’t just breaking barriers; it’s healing them. Cleared for acute wound care and atopic dermatitis, this powerhouse formula is now on the brink of a bigger leap. Turn, the company behind Hexagen, is paving the way to expand its applications, proving there’s much more to its potential than meets the eye.
Turn just locked in a game-changing commitment—up to $75M in investment from GEM Global Yield Fund. This private equity boost is tied to the company’s plans to go public, setting the stage for Turn to make bold moves in the market spotlight..2
Turn is rolling out institutional, accredited, and unaccredited investors to participate in their current crowdfunding campaign — but only until January 2025.3
Nvidia says it’s missing out on a jaw-dropping $8 billion per quarter thanks to U.S. restrictions on chip sales to China. On its latest earnings call, the company name-dropped “China” 27 times — more than the last four quarters combined.
Why? The H20 chip — designed to comply with trade rules — got the axe in April under Trump-era export controls. That wiped out one of Nvidia’s biggest overseas revenue streams.
Let’s pause.
Eight. Billion. Dollars.
Every 90 days. Gone.
That’s more than McDonald’s global revenue each quarter.
It’s more than 19 entire S&P 500 companies combined.
It even exceeds the total quarterly sales of 384 S&P firms.
If we were losing $8B every few months, we’d never shut up about it either.
The sting is sharper now that the company’s data center growth is starting to level off. Back when those numbers were booming, the China gap was painful — but manageable. Today, it's a glaring wound.
In a single month, Elon Musk’s SpaceX launched nearly 400 Starlink satellites — more than ever before. That brings the total to 8,800+ launched since 2019, with around 7,600 still actively orbiting Earth.
Fun fact: Starlink now represents a staggering portion of all satellites launched since Sputnik first beeped from orbit in 1957.
Together with State Street Global Advisors
SPY: The first and most traded S&P 500 ETF
Looking for fast, deep exposure to U.S. stocks? SPY is your one-stop shop.
In fact, SPY traded 3.64x more than Apple last year — and outpaced Microsoft, Meta, and Amazon combined.²
Want a piece of the S&P 500®? SPY’s your ticket.
Applied Digital and CoreWeave — soared after locking in 15-year deals with each other
DraftKings and Flutter Entertainment — tumbled after Illinois rolled out an unexpected tax hike
Steel stocks — rallied hard after Trump slapped new tariffs on metal imports
Presented by Atombeam
Big tech, small data… Why are industry leaders like NVIDIA, Intel and Ericsson partnering with Atombeam?1 It’s the company reimagining machine communication — and potentially the future of big tech. That’s thanks to Neurpac, Atombeam’s patented software technology that can reduce the size of low-entropy data by an average of 75%.
Lightning fast… Neurpac enables 2-4x more data to be sent faster and more securely over existing networks—no hardware upgrades — just smart, AI-powered software.
To the moon and back… The U.S Space Force and U.S. Air Force have already been on Atombeam’s customer books — and the company’s potential market is still gaining ground. Atombeam is in discussions with multiple companies, ranging from a major packaging brand to an EV enterprise.
$16M has already been invested into the company. You can invest before the round closes in 29 days.2
1 The partnership relationship varies between companies and can include the following: inclusion on a preferred vendor list, invitations to participate in certain forums; listed on the other company's website, and introduction and networking opportunities.
Advertiser's disclosures:
¹ The Company's Formula (Gx-03/Hexagen/Atopx) Has Received 510k Marketing Approval As A Medical Device Indicated For The Management Of Symptoms Related To Atopic Dermatitis/Eczema. The Formula Has Not Received Approval As A Drug For The Treatment Of Eczema Or Onychomycosis.
² A plan to IPO is no guarantee that an actual IPO will occur.
³ Please read the offering circular and related risks at StartEngine’s Turn Therapeutics webpage. This is a paid advertisement for Turn Therapeutics Regulation CF Offering. This Reg CF offering is made available through StartEngine Primary, LLC, member FINRA/SIPC.
Investing in private company securities is not suitable for all investors because it is highly speculative and involves a high degree of risk. It should only be considered a long-term investment. You must be prepared to withstand a total loss of your investment. Private company securities are also highly illiquid, and there is no guarantee that a market will develop for such securities.
